Table 3.

Effects of clinical basal characteristics, preoperative and postoperative blood tumor biomarkers on tumor recurrence survival in stage II-III CRC analyzed by univariate and multivariate Cox proportional hazard regression.

Parameters	Univariate analysis							Multivariate analysis
	B	Wald	P-value	HR	95.0% CI			B	Wald	P-value	HR	95.0% CI
Gender (Female vs. Male)	-0.157	0.111	0.739	0.855	0.339	2.154
Age (>62 vs.≤62 yrs)	0.236	0.237	0.626	1.266	0.490	3.270
Tumor location (Colon vs. Rectum)	0.225	0.202	0.653	1.252	0.470	3.338
T stage (T3-4 vs. T1-2)	0.532	0.503	0.478	1.702	0.391	7.404
N stage (N1-2 vs. N0)	1.057	4.471	0.034	2.879	1.080	7.672
TNM stage (III vs. II)	1.301	6.112	0.013	3.674	1.309	10.306		1.331	6.218	0.013	3.786	1.330	10.780
Tumor differentiation (Well/Moderate vs. Poor)	-0.624	0.972	0.324	0.536	0.155	1.852
Preoperative CA125 (Positive vs. Negative)	1.060	4.982	0.026	2.886	1.138	7.318
Preoperative CA19-9 (Positive vs. Negative)	1.171	4.947	0.026	3.226	1.149	9.056
Preoperative CA72-4 (Positive vs. Negative)	0.511	0.651	0.420	1.667	0.482	5.765
Preoperative CEA (Positive vs. Negative)	0.344	0.506	0.477	1.410	0.547	3.639
Preoperative CTCs (Positive vs. Negative)	-0.048	0.006	0.939	0.953	0.276	3.292
Postoperative CA125 (Positive vs. Negative)	1.027	4.436	0.035	2.793	1.074	7.264
Postoperative CA19-9 (Positive vs. Negative)	1.152	4.105	0.043	3.165	1.038	9.649
Postoperative CA72-4 (Positive vs. Negative)	1.721	11.823	0.001	5.589	2.096	14.904		1.736	11.316	0.001	5.675	2.064	15.604
Postoperative CEA (Positive vs. Negative)	1.340	5.507	0.019	3.821	1.247	11.705
Postoperative CTCs (Positive vs. Negative)	1.490	8.869	0.003	4.435	1.664	11.820		1.008	4.178	0.041	2.739	1.042	7.200

Abbreviations: CRC, colorectal cancer; CTCs, circulating tumor cells; CEA, carcinoembryonic antigen; CA125, carbohydrate antigen 125; CA19-9, carbohydrate antigen 19-9; CA72-4, carbohydrate antigen 72-4; HR, hazard ratio; CI, confidence interval. Note, Bold, indicates the association was significant.